The Post-treatment Cancer Immunobiology Laboratory Research Focus
In the light of therapy-induced or organ-specific cues in the cancer macroenvironment, the Post-treatment Cancer Immunobiology Laboratory leverages genetically modified mice and clinical samples for cellular-and-molecular immunology-based high-throughput analyses, thus delving into the mechanisms of how the acquired inflammation and epigenetic regulation impose therapy response or resistance.
In particular, they are looking at how post-treatment inflammation reshapes the function of anti-tumour T cells and other underrepresented immune populations, aimed to explore whether the underlying molecular traits can apply to tailoring T cell-based immunotherapy and new drug development.
Gallery
Research Team
The Post-treatment Cancer Immunobiology Laboratory Publications
Zhang H, Luo X, Yang W, Wu Z, Zhao Z, Pei X, Zhang X, Chen C, Lei J, Shi Q, Zhao Q, Chen Y, Wu W, Zeng Z, Ju H, Qiu M, Liu J, Shen B, Chen M, Chen J, Deng C, Xu R, Hou J (Senior Author). YTHDF2 upregulation and subcellular localization dictate CD8 T cell polyfunctionality in anti-tumor immunity. Nat Commun. 2024 Nov 5;15(1):9559
Yang Z, Wang X, Fu Y, Wu W, Hu Z, Lin Q, Peng W, Pan Y, Wang J, Chen J, Hu D, Zhou Z, Xu L, Zhang Y, Hou J (Senior Author), Chen M. YTHDF2 in peritumoral hepatocytes mediates chemotherapy-induced antitumor immune responses through CX3CL1-mediated CD8 T cell recruitment. Mol Cancer. 2024 Sep 6;23(1):186
Chen P, Dong Z, Zhu W, Chen J, Zhou Y, Ye Q, Liao X, Tan Y, Li C, Wang Y, Pang H, Wen C, Jiang Y, Li X, Li B, Aimaier A, Lin L, Sun J, Hou J (Senior Author), Tang L, Hou J, Li Y. Noncanonical regulation of HOIL-1 on cancer stemness and sorafenib resistance identifies pixantrone as a novel therapeutic agent for hepatocellular carcinoma. Hepatology. 2024 Aug 1;80(2):330-345.